Home Apoptosis Bcl-6

Bcl-6

Other Apoptosis Related Inhibitors

Caspase Bcl-2 p53 Ferroptosis PD-1/PD-L1 Survivin TNF-alpha MDM2/MDMX KRas IAP
Cat.No. Product Name Information Product Use Citations Product Validations
S8591 FX1 FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. This compound shows great selectivity against a panel of 50 different kinases. 10 μM of this chemical fails to significantly inhibit of any of these kinases. It induces apoptosis.
Frontiers in Oncology, September 22, 2025, 1616519
Frontiers in Oncology, September 22 2025, 15:1616519
Life Science Alliance, October 27 2025, e202503335
S6937 BI-3802 BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. This compound inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. It exhibits antitumor activity.
Adv Sci (Weinh), 2025, 12(31):e01284
Phytomedicine, 2024, 133:155944
Cancer Research, 2023, 3624-3635
S8735 BI-3812 BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM.
Journal of the American Chemical Society, 2025, 44739-44758
American Journal of Transplantation, 2024, 2157-2173
Haematologica, 2022, 10.3324/haematol.2022.280879
S8250 79-6 (CID5721353) 79-6 (CID5721353), a BCL6 inhibitor, has a Kd value of 138 μM.
Cell Reports Medicine, 2022, 100744
Cell Rep Med, 2022, 3(9):100744
E5965New BMS-986458 BMS-986458 is a potent, highly selective, orally bioavailable CRL4 CRBN E3 ubiquitin ligase-dependent BCL6 ligand directed degrader, which exhibits the potential to treat B-cell non-Hodgkin Lymphoma.